A Phase 2 Proof-of-Concept Study of CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- Sponsors XERIS Pharmaceuticals
- 13 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 13 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.
- 20 Oct 2016 New trial record